Description: NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Home Page: www.nucana.com
NCNA Technical Analysis
3 Lochside Way
Edinburgh,
EH12 9DT
United Kingdom
Phone:
44 13 1357 1111
Officers
| Name | Title |
|---|---|
| Mr. Hugh Stephen Griffith | Founder, CEO & Exec. Director |
| Mr. Donald Munoz | Chief Financial Officer |
| Mr. David Harrison | Head of Translational Medicine |
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer |
| Prof. Christopher B. Wood FRCS, M.D., Ph.D. | Chief Medical Officer |
| Ms. Theresa Bruce | Sr. VP of Clinical Operations |
| Ms. Elisabeth Oelmann | Sr. VP of Medical & Clinical Devel. |
| Martin Quinn | Company Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6476 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-09-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |